HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 5%. The European Commission has approved a new indication for Sujigilibab.

CSTONE PHARMA-B (02616) surged more than 5%, as of the time of publication, up 5.32% to 5.94 Hong Kong dollars, with a turnover of 8.2294 million Hong Kong dollars. On the news front, on November 25, CStone Pharma announced that the European Commission (EC) has approved the new indication for sugolixumab: as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after platinum-based chemoradiotherapy (CRT) and have PD-L1 expression 1%, without EGFR sensitive mutations or ALK, ROS1 genomic alterations. Dr. Yang Jianxin, CEO, President of R&D, and Executive Director of CStone Pharma, stated that following the EC's initial approval of sugolixumab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024, the approval of this new indication only a year later marks the complete coverage of sugolixumab from stage III to stage IV NSCLC in Europe, providing a new treatment option for a broader range of patients.